During the corresponding time, Irhythm Holdings Inc recorded a revenue increase by 20.62 % year on year, sequentially revenue grew by 12.45 %. While revenue at the Irhythm Holdings Inc 's corporate clients
Irhythm Holdings Inc's Comment on Sales, Marketing and Customers
iRhythm provides ambulatory cardiac monitoring services using device-based technology to licensed healthcare providers, including physicians. Its customers and market segments include healthcare providers, physicians, payors, patients, and lay caregivers. The company operates independent diagnostic testing facilities (IDTFs) and maintains working relationships with healthcare providers to support clinical acceptance and adoption of its services.
iRhythm Technologies Secures Japanese Regulatory Approval for AI-Powered Zio ECG Monitoring System Amid Impressive Revenue GrowthiRhythm Technologies Inc. has announced an essential milestone in its expansion efforts with the recent regulatory approval of its Zio ECG Monitoring System in Japan. This marks the first product in the healthcare sector to offer arrhythmia monitoring services powered by artificial intelligence (AI), underscoring iRhythm’s commitment to innovation and excellence in cardiac care.In an impressive display of financial health, iRhythm reported a revenue increase of 19.68% for the second quarter of 2024, bringing its total revenue to $536 million a new record for the company. The com...
iRhythm Technologies Enters License Agreement with BioIntelliSense for Advanced Ambulatory Cardiac Monitoring Solutions In a strategic move that stands to enhance the capabilities of ambulatory cardiac monitoring (ACM), iRhythm Technologies has entered into a licensing agreement with BioIntelliSense. This agreement grants iRhythm exclusive rights to BioIntelliSense’s patented technologies, including pulse oximetry, accelerometry, and non-invasive blood pressure trending, to be implemented within the ACM market.iRhythm Technologies, a company specializing in digital health solutions for cardiac arrhythmias, has positioned itself as a leader in the ACM space. The inclusion of BioIntelliSense’s innovative s...
At the recent European Society of Cardiology (ESC) Congress 2024, iRhythm Technologies Inc. unveiled its groundbreaking findings from the GUARD-AF trial, marking a significant milestone in the realm of cardiac care. This pivotal study investigated the efficacy of long-term monitoring in patients with atrial fibrillation (AF), a condition that affects millions globally and poses serious risks, including stroke and heart failure. The trial s outcomes not only reinforced iRhythm s leading position in the digital health sector but also stirred excitement within the medical community regarding the future of AF management.The GUARD-AF trial examined the effectiveness of iRhythm s Zio® service, an advanced, wearab...
Irhythm Holdings Inc’s Comment on Sales, Marketing and Customers
iRhythm provides ambulatory cardiac monitoring services using device-based technology to licensed healthcare providers, including physicians. Its customers and market segments include healthcare providers, physicians, payors, patients, and lay caregivers. The company operates independent diagnostic testing facilities (IDTFs) and maintains working relationships with healthcare providers to support clinical acceptance and adoption of its services.
Sources:
Irhythm Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Irhythm Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Irhythm Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
98.4 %